🇺🇸 SECKAZIA THERAPEUTICS LTDQwen · 实盘不做把握 1/10不做原因:不是事件
北京时间·🕒 发布 08-31 19:30:30·⟳ 抓取 08-31 19:31:01 +31s·⚡ 决策 09-01 00:02:12 +4h31m·56.9 天前
Kazia Therapeutics 6-K备案：公司更换官网域名，纯行政性披露
该6-K仅告知公司官网URL变更，属于例行行政备案，不含任何财务、临床、业务、监管或战略实质信息，不构成交易催化。
📄 原文KAZIA THERAPEUTICS LTD↗ 原文
----- ea0303976-6k_kazia.htm ----- 6-K 1 ea0303976-6k_kazia.htm REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITI…
不做 Kazia Therapeutics Limited（KZIA.US）
6-K内容仅为公司官网URL变更的例行行政备案，不含任何财务、临床、业务、监管或战略实质信息，不构成交易催化，无方向、无edge。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Kazia Therapeutics于2026年8月31日向SEC提交6-K，内容仅为官网域名从kaziatherapeutics.com变更为kaziatx.com，并纳入已有注册声明。无任何收入、临床进展、订单、指引、监管或资本结构变化。该披露对股价无方向性影响，不存在可交易的edge。
🔎 新鲜度:最早出现 2026-08-31 · 扩散 low · price-in 风险 low ↗
先例如何影响了这次决策
对本次决策的影响:无需先例支撑，事件不构成催化
方向:无适用先例，事件本身无交易含义
原文全文
展开原文 · 2,077 字
----- ea0303976-6k_kazia.htm -----
6-K
1
ea0303976-6k_kazia.htm
REPORT OF FOREIGN PRIVATE ISSUER
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of August 2026
Commission File Number: 000-29962
Kazia Therapeutics Limited.
(Exact Name of Registrant as Specified in Its Charter)
Three International Towers Level 24 300 Barangaroo
Avenue Sydney NSW 2000
(Address of principal executive offices)
Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F
☒
Form 40-F
☐
INFORMATION CONTAINED IN THIS FORM 6-K REPORT
On August 28, 2026, Kazia Therapeutics Limited
(the “Company”) launched a new website. The new website can be found at www.kaziatx.com.
Any prior references to the Company’s website,
including references to www.kaziatherapeutics.com, in the Company’s filings with the Securities Exchange Commission (the “SEC”)
should be read to refer to the new URL, www.kaziatx.com, as applicable.
The new website has been designed to provide investors,
customers, and other stakeholders with enhanced access to information regarding the Company’s business, products, services, clinical
trials, and corporate developments. We encourage investors, patients, business partners, researchers, and other stakeholders to review
the information we post on our website, in addition to following our press releases and SEC filings.
Incorporation by Reference
The Company hereby incorporates by reference the
information contained herein into the Company’s registration statements on Form F-3 (File Nos.
333-276091
,
333-281937
and
333-294392
).
1
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Kazia Therapeutics Limited.
Date: August 31, 2026
By:
/s/ John Friend
Name:
John Friend
Title:
Chief Executive Officer
2
6-K
1
ea0303976-6k_kazia.htm
REPORT OF FOREIGN PRIVATE ISSUER
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of August 2026
Commission File Number: 000-29962
Kazia Therapeutics Limited.
(Exact Name of Registrant as Specified in Its Charter)
Three International Towers Level 24 300 Barangaroo
Avenue Sydney NSW 2000
(Address of principal executive offices)
Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F
☒
Form 40-F
☐
INFORMATION CONTAINED IN THIS FORM 6-K REPORT
On August 28, 2026, Kazia Therapeutics Limited
(the “Company”) launched a new website. The new website can be found at www.kaziatx.com.
Any prior references to the Company’s website,
including references to www.kaziatherapeutics.com, in the Company’s filings with the Securities Exchange Commission (the “SEC”)
should be read to refer to the new URL, www.kaziatx.com, as applicable.
The new website has been designed to provide investors,
customers, and other stakeholders with enhanced access to information regarding the Company’s business, products, services, clinical
trials, and corporate developments. We encourage investors, patients, business partners, researchers, and other stakeholders to review
the information we post on our website, in addition to following our press releases and SEC filings.
Incorporation by Reference
The Company hereby incorporates by reference the
information contained herein into the Company’s registration statements on Form F-3 (File Nos.
333-276091
,
333-281937
and
333-294392
).
1
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Kazia Therapeutics Limited.
Date: August 31, 2026
By:
/s/ John Friend
Name:
John Friend
Title:
Chief Executive Officer
2
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。